Evidence map›Paper›PMID 39456577›Full record

ReviewCancers2024

Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.

Annalisa Arcari, Lucia Morello, Elena Borotti, Elena Ronda, Angela Rossi, Daniele Vallisa

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. The importance ofMolecular biology research communications · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Annalisa ArcariHematology Unit, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.ORCID 0000-0001-5337-5947
Lucia MorelloHematology Unit, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.
Elena BorottiBone Marrow Transplant Laboratory, Molecular Diagnostic and Stem Cells Manipulation, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.ORCID 0009-0004-1184-8709
Elena RondaBone Marrow Transplant Laboratory, Molecular Diagnostic and Stem Cells Manipulation, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.ORCID 0000-0002-5920-7386
Angela RossiBone Marrow Transplant Laboratory, Molecular Diagnostic and Stem Cells Manipulation, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.
Daniele VallisaHematology Unit, Ospedale Guglielmo da Saliceto, Azienda USL di Piacenza, 29100 Piacenza, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie the disease's pathogenesis. Very heterogeneous prognostic subgroups have been identified by the mutational status of immunoglobulin heavy variable genes (

Indexed as

chronic lymphocytic leukemiaminimal residual diseaseprecision medicine

Identifiers

PMID39456577
PMCPMC11505876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.